Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 01011)

POSITIVE PROFIT ALERT

This announcement is made by China NT Pharma Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that based on the preliminary assessment of the unaudited consolidated management accounts of the Company for the six months ended 30 June 2017 (the "**Accounts**"), the Group expects to record an increase in net profit by approximately 50% for the six months ended 30 June 2017 as compared to the corresponding period of 2016. Such increase is primarily attributable to innovative drug Xi Di Ke and brand-name drug Miacalcic which contributed to the profit of the Group.

As at the date of this announcement, the Company is still in the process of preparing the interim results of the Group for the six months ended 30 June 2017. The information as set out above is only based on a preliminary assessment by the Board on the information currently available to it, including the Accounts, which have not been finalized and not been reviewed or audited by auditors or the audit committee of the Company. Shareholders and potential investors should read the interim results of the Company for the six months ended 30 June 2017 for details of the Group's financial performance, which are expected to be published before the end of August 2017.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 10 July 2017

As at the date of this announcement, the executive directors of the Company are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive directors of the Company are Dr. Qian Wei and Mr. Ge Jianqiu; and the independent non-executive directors of the Company are Mr. Patrick Sun, Dr. Lap-Chee Tsui and Mr. Yu Tze Shan Hailson.